Emory University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).
Emory University: 1,208 sponsored US clinical trials, 208 recruiting.
Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.
Top-decile sponsor footprint
Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,208 total, page 6 of 25
Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation
NCT04018937
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
NCT03756896
VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma
NCT03769155
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
NCT03468218
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
NCT03368963
Tango for Alzheimer's Disease Patients' Caregivers
NCT03269149
RBC Irradiation, Anemia and Gut Injury
NCT02741648
Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
NCT02574728
Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S
NCT01984710
Deep Brain Stimulation for Treatment Resistant Depression
NCT00367003
Quantifying Multi-step Avoidance in Anxiety
NCT07203027
Integrating Supports to Promote PrEP for Black Adolescents Working With Apps- Atlanta
NCT07535346
Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function
NCT07414810
Integrating Supports to Promote PrEP for Black Adolescents Working With Apps- Alabama
NCT06876324
Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty
NCT07624526
Baricitinib Curative Repression of HIV-1
NCT07209267
Neuroplastic Changes Due to an Exercise Intervention That Aid in Lower Limb Recovery After Subcortical Stroke
NCT07663292
Assessing Molecular Mechanisms and Effects of Music Therapy in Youth With Sickle Cell Disease Using Single-cell RNA-sequencing
NCT07562451
Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait
NCT07189819
Rapid Evacuation and Access of Cerebral Hemorrhage Registry
NCT07651631
JAK Signaling in Depression and Cognition in Male Football Players
NCT07608796
Early Diagnostic Telehealth Pilot for Moderate- and High-Risk Children: Evaluating Assessment Protocols and Efficiency in Georgia's Early Intervention Program
NCT07623759
Psilocybin-Assisted Therapy
NCT07332143
Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV
NCT06233331
Sleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients
NCT07336277
Comparison of Sepsis Prediction Algorithms
NCT05943938
Linking Individuals Needing Care for Substance Use Disorders to Peer Coaches & Across INcarceration Settings
NCT07563517
Improving Maternal and Child Health Through Point-of-care STI Testing
NCT07290439
Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
NCT07428746
CGM Use in Heart Failure
NCT07045298
Temporal Interference in Psychiatry (TIP): Neuromodulation Using Temporal Interference
NCT07558759
Novel Sepsis Sub-phenotypes Based on Trajectories of Vital Signs
NCT05826223
Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients with Hypoplastic Left Heart Syndrome (HLHS)
NCT06461676
Automated Insulin Delivery for Inpatients With Dysglycemia
NCT06418880
Revealing Protective Immunity to Influenza Using Systems Immunology
NCT06501963
ACEs Referral From PED
NCT06574633
Caregiving While Black: LIVE
NCT06605391
Daily Doxycycline to Inform Sexually Transmitted Infection Prophylaxis Regimens
NCT06545656
Linking Individuals Needing Care for Substance Use Disorders to Peer Coaches
NCT05847621
Green Hysteroscopy
NCT06379841
Precision Resuscitation With Crystalloids in Sepsis
NCT06253585
Go Sun Smart Georgia Evaluation
NCT06418672
Chronic Exertional Compartment Syndrome (CECS) Treated With Abobotulinumtoxin A
NCT05466539
Active You: Walk, Dance, and Tone Your Abs to Reduce Your Risk of Diabetes
NCT06127251
Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial
NCT05946551
Shift-and-persist and Cardiometabolic Markers Among Women in Puerto Rico
NCT06250738
Aldena STAR Particles
NCT06004973
Improving Sleep and AD Biomarkers
NCT06029894
Promoting Engagement and COVID-19 Testing for Health
NCT06141850
Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)
NCT05545072
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 154 |
| Phase 2 | 190 |
| Phase 3 | 36 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Emory University pipeline
208 recruiting of 1,208 indexed (17% open); 767 completed (63%).
Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).
Top condition: Depression (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Emory University: open-pipeline peers nationwide
Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,208 trials (± recruiting share)
- Northwestern University · 1,209 trials · 15% recruiting
- University of Pittsburgh · 1,238 trials · 13% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Baylor Research Institute · 17% recruiting · 180 trials
- National Institute on Alcohol Abuse and Alcoholism (NIAAA) · 17% recruiting · 93 trials
- Hunter College of City University of New York · 17% recruiting · 29 trials
- Ochsner Health System · 17% recruiting · 29 trials
Related
What to do with this Emory University page
1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.
- 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Emory University pipeline card: 1,208 registered trials from official public datasets.Report a data error.